Cellecta

The IP is based on the research of Emmanuelle Charpentier from the Hannover Medical School in Germany and Umea University in Sweden.

The company aims to commercialize the platform and related services by late 2018.

Using enhancements to RT-PCR, the firm is able to detect all protein-coding genes in a single-tube multiplex reaction, reducing costs for large-scale projects.

The genetic screening firm validated the modifications with a Phase I SBIR grant from NIH and is seeking a Phase II grant to target critical protein domains.

The company said the library will be made freely available to academic and non-profit investigators through the DECIPHER Project.

Products & Services

Premium

Exiqon, Cellecta

The company will use the NCI funding to discover and validate gene targets involved in breast cancer that may affect a panel of epithelial cells involved in breast cancer.

Products & Services

Premium

Cellecta

The partners will use Ariadne’s software to combine siRNA screening data with information gleaned from scientific literature in order to develop a comprehensive database of prostate cancer-related information.

Pages

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.